Prostate-specific antigen levels in patients receiving long-term dialysis.
OBJECTIVE
To investigate the effect, if any, of renal failure upon prostate-specific antigen (PSA) levels and the validity of PSA estimation as a marker of prostatic disease in renal failure.


METHODS
PSA was measured in 65 men (median age 67 years, range 39-84) on regular haemodialysis and 37 men (median age 70 years, range 42-77) on continuous ambulatory peritoneal dialysis (CAPD). Patients with a PSA level > 4 ng/mL underwent prostatic biopsy guided by transrectal ultrasonography.


RESULTS
There was no evidence of an artefactual elevation of PSA attributable solely to renal failure. All eight patients with a PSA level > 4 ng/mL had prostatic disease.


CONCLUSIONS
PSA measurements in patients with end-stage renal failure treated by dialysis remain a useful marker of prostatic disease.
Harper
L
L
Department of Nephrology, St Bartholomew's Hospital, London, UK.
McIntyre
C W
CW
MacDougall
I C
IC
Meyer
P
P
Raine
A E
AE
Baker
L R
LR
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis
D017430:Prostate-Specific Antigen